Celcuity (CELC) Other Accumulated Expenses (2018 - 2026)
Celcuity's (CELC) quarterly Other Accumulated Expenses came in at $20.9 million in Q4 2025, up 280.96% YoY from $5.5 million in Q4 2024, and up 280.96% on a QoQ basis from $5.5 million in Q4 2024.
Celcuity (CELC) Other Accumulated Expenses (2018 - 2026) Analysis & Trends
Celcuity (CELC) has 4 years of Other Accumulated Expenses data on file, last reported at $20.9 million in Q4 2025.
- Quarterly Other Accumulated Expenses rose 280.96% year-over-year to $20.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $20.9 million (up 280.96% YoY) and the FY2025 annual result came in at $20.9 million, up 280.96% from the prior year.
- Other Accumulated Expenses grew to $20.9 million in Q4 2025, from $5.5 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $20.9 million in Q4 2025 to a low of $5.5 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.58 Mn |
| Dec 31, 2025 | 20.87 Mn |
| Dec 31, 2024 | 5.48 Mn |
| Dec 31, 2019 | 112,746.00 |
| Dec 31, 2018 | 52,347.00 |